Unleashing Bacteria-Based Therapy for Bladder Cancer: Recent Bioengineered agent and Bacterial-Derived Molecules
Unleashing Bacteria-Based Therapy for Bladder Cancer: Recent Bioengineered agent and Bacterial-Derived Molecules
Mahdi Abbasi,1,*Fatemeh Bayat Sarmadi,2Ali Hajiaghababaee,3Amirreza Ghafourian,4
1. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran 2. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran 3. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran 4. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Introduction: Bladder cancer poses a formidable global health challenge, necessitating a novel approach to therapeutic intervention. In response, bacteria-based therapies have emerged as promising contenders in this dynamic landscape. This review delves into the potential of bacteria-based therapy for bladder cancer, with a keen focus on the transformative roles of novel bioengineered agents and bacterial-derived molecules.
Methods: Articles related to bacterial therapy for bladder cancer, specifically in the context of bioengineered agents and bacterial-derived molecules, were screened on PubMed, Google Scholar, ScienceDirect, and other Current Contents databases. Priority was given to articles with free full-text access. Relevant and recent publications were meticulously analyzed, and pertinent materials were extracted for inclusion in this review.
Results: The spotlight of our findings rests on the potential of novel bioengineered agents, a class encompassing genetically modified bacteria and fusion proteins. This innovative approach holds promise for targeted tumor destruction, allowing precision in treatment. This form of therapy presents the prospect of personalized interventions, minimizing damage to healthy tissue while tailoring treatments for maximal therapeutic efficacy. The review underscores the potential of these bioengineered agents, notably genetically modified bacteria and fusion proteins, in achieving targeted and selective tumor-killing. Such agents offer the advantage of personalized treatment with minimal off-target effects, ensuring treatments are customized for optimal therapeutic outcomes. However, the utilization of these agents requires careful consideration of challenges, including optimizing dosages, managing potential long-term effects, and addressing the emergence of resistance mechanisms. To enhance therapeutic effectiveness, the recombination of bacterial agents through genetic modifications emerges as a strategic avenue, promising synergistic benefits that augment tumor recognition, immune activation, and drug delivery capabilities. Additionally, bacterial-derived molecules, encompassing enzymes, antimicrobial peptides, toxins, and antibiotics, reveal diverse anticancer properties. These molecules hold potential in various aspects, from inducing apoptosis to inhibiting oncogenic pathways and activating antitumor immune responses. Such multifaceted properties highlight their potential as valuable therapeutic tools in the fight against bladder cancer.
Conclusion: Bacteria-based therapy represents a promising frontier in the battle against bladder cancer, offering multifaceted approaches through novel bioengineered agents and bacterial-derived molecules. Despite their potential, challenges including dosing refinement, long-term consequences, and resistance mechanisms require thorough investigation for safe and effective clinical translation. Recombination strategies hold promise in overcoming these challenges and enhancing therapeutic efficacy. The extensive potential of bacteria-based therapy calls for further research and rigorous clinical validation to fully unlock its benefits in bladder cancer treatment.